HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

Mantle cell lymphoma (MCL) is a highly aggressive and heterogeneous B-cell lymphoma. Though Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown great efficacy as a single agent for MCL treatment, the real-world use of ibrutinib is still subject to limitations. Our previous study has shown t...

Full description

Bibliographic Details
Main Authors: Ziwen Lu, Zhixin Wang, Zhigang Tu, Hanqing Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
Hsp90
ganetespib
mantle cell lymphoma
Btk
ibrutinib
apoptosis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.864194/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.864194/full

Similar Items